Page 1 of 27

CURRICULUM VITAE Name: Khosrow Kashfi, PhD, MSc, FRSC

Home Address 3 Bonaire Drive, Dix Hills, NY 11746 and Phone: 516-413-5450

Work Address Department of Molecular, Cellular and Biomedical Sciences and Phone: The Sophie Davis School of Biomedical Education City University of New York School of Medicine 160 Convent Avenue, Harris Hall, Suite 205C

New York, NY 1003, USA Tel: 212-650-6641 FAX: 212-650-7692 email: Kashfi@med.cuny.edu Education: High School: Seaford College, Petworth Sussex, England, Graduated 1971

Undergraduate: Kingston Polytechnic, Surrey, England, B.Sc. (Hon.) in Chemistry, 1974

Postgraduate: Cranfield Institute of Technology, Bedford, England, M.Sc. in Polymer Physics and Engineering, 1976

University of Tennessee, Memphis TN Ph.D. in Pharmacology, 1992

Postdoctoral: Cornell University Medical College (1993-1995) Rockefeller University (1995-1997) Societies, Honors and Awards: 1974-1976 Full Scholarship for M.Sc. degree

1985 Licentiate of The Royal Society of Chemistry, England

1993 Full member, Biochemical Society, England

1996 Sigma Xi

1996 Regular member, Society for Experimental Biology and Medicine

1997 Member, American Chemical Society

2006 Instructor of the year award by the 2006 graduating class of The City University of New York Medical School

2010 Elected Fellow of The Royal Society of Chemistry, England

2011, 2012 Minority-Serving Institution Faculty Scholar in Cancer Research 2014 Award from The American Association for Cancer Research

Page 2 of 27

Employment:

1999-Present City University of New York School of Medicine, The Sophie Davis School of Biomedical Education,

Associate Medical Professor, Department of Cellular, Molecular, Medical Sciences Tenure, 2007

1999-2018 City University of New York Medical School, The Sophie Davis School of Biomedical Education,

Chemistry Program Director,

2009-2013 Director, Medical and Physician Assistant Pharmacology Courses

2002-2006 Director, Medical Biochemistry Program

2003-Present State University of New York at Old Westbury Adjunct Full Professor of Organic Chemistry & Biochemistry

2006-Present State University of New York at Stony Brook Adjunct Associate Professor, Department of Medicine Division of Cancer Prevention 1997-2005 The Rockefeller University, Laboratory of Clinical Microbiology and

Immunology, Adjunct Faculty 1997-1999 Department of Physical Sciences, Kingsborough Community College of The City University of New York, Assistant Professor 1995-1997 Bronx Lebanon Hospital, Bronx, New York, Course Coordinator in Pharmacology for The Physician Assistant Program 1994-1997 Department of Natural and Applied Sciences, LaGuardia Community College of The City University of New York, Adjunct Assistant Professor 1993-1995 Department of Medicine, Division of Digestive Diseases, The New York Hospital-Cornell Medical Center,

Postdoctoral Fellow in Medicine 1987-1992 Department of Pharmacology, College of Medicine, University of Tennessee, Memphis, Teaching Assistant 1985-1986 Department of Medicinal Chemistry, University of Tennessee, Memphis, H.S. Van Vleet Research Fellow in Medicinal Chemistry 1984-1985 Christian Brothers University, Memphis, Tennessee, Lecturer in Chemical Engineering 1980-1984 Loxdent Chemical Company, Ltd., England, Processing Engineer

1976-1980 Department of Mechanical Engineering, Imperial College of Science and Technology, London University, England, Research Assistant

Page 3 of 27

Teaching Experience: A. The following courses have been taught by me at various times:

1. Organic chemistry I & II 6. Medicinal organic chemistry II 2. Chemistry for Allied Health Students 7. Physiology 3. General Chemistry I & II 8. Thermodynamics I & II 4. Biochemistry 9. Polymer science 5. Pharmacology (Entire PA Program, 10. Material selection course director) B. Courses and topics taught at CUNY Medical School 1999- current General Chemistry, entire course

Organic Chemistry, selected topics As Program Director, I reorganized the courses and introduced small group study sessions, “Peer-Led Team Learning”. This has proved to be very successful. Also, students get periodic Progress Reports, which informs them of how they are doing in class and what steps are needed to improve standing. 2000-current GI Pharmacology (entire unit) 2000-2004 GI Physiology (entire unit) 2000-2002 Neuropharmacology 2002, 2005- Cardiovascular Pharmacology present Drugs used in the treatment of heart failure, hypertension,

hypercholesterolemia 2000-2008 Conducted 10 PBL sessions each year in pharmacology, and the only PBL session in GI physiology 2002-2004 Biochemistry: Cytochrome P450s, Gluconeogenesis,

Metabolic Interrelationships

As Program Director, I introduced genetic disease presentations by all students, worked very closely with our own faculty and faculty from Cornell University Medical College to ensure a course that met all expectations of the National Board of Medical Examiners. I also introduced 6 PBL sessions (conducted by myself), the cases for which were purchased from Harvard Medical School. In 2003 mini-boards in biochemistry, 20% of the class scored above the 90th percentile. 2004-2009 Molecules-to-Cells: This is a new course in which I have taught the

following topics: Protein-Ligand interactions; Receptors; Enzymes, enzyme kinetics, enzyme regulation; Glycolysis; Fatty acid synthesis, Gluconeogenesis, Major Lipids: Fatty acids, Eicosanoids; Cholesterol and its derivatives; Liporproteins and cholesterol transport, Reactive oxygen species.

As Chair of our Curriculum Committee, I was intimately involved in the formulation of this course and its implementation. 2005- 2018 Bio-Organic Chemistry

This is a new one-semester course which I introduced in 2005. This course integrates organic and biochemistry, diffusing the boundary between the two areas which should help better prepare our students for entry into our Molecules-to-Cells course.

Page 4 of 27

Faculty Development Workshops 1) October 1999--Ovid Medline for Efficient, Research-Targeted Medical Literature Searching. Instructor, CCNY Assistant Professor Claudia Lascar, Science Engineering Librarian. 2) November 1999--Deborah Danoff, M.D., AAMC, Assistant Vice-President in Medical Education 3) February 2000--˜Writing Clincial Vignettes and USMLE-Type Examination Questions. Workshop Leaders, Susan M. Case and David. B. Swanson, Ph.D. Association of American Medical Colleges 4) March 2000--Guidelines for Creating Teaching Portfolios, Ellen Smiley, Ph.D., CCNY Assistant Provost 5) November 2000--CurrMit (Curriculum Management Information Tool) Al Salas, Project Director/Senior Staff Associate, Division of Medical Education 6) December 2000—CCNY Anti-sexual Harassmant Student Supervision: The following students have been mentored by me (1999-present): Master’s Thesis:

Nicole E. Neptune, Department of Chemistry, City College of CUNY (2000).

Title: Comparative Effects of Hemipalmitoylcarnitinium Stereoisomers on Hepatic Mitochondrial Carnitine Palmitoyltransferases.

PhD Thesis:

Member of PhD dissertation committees: Ms. Phyllis J. Langone, Department of Biochemistry, College of Staten Island, City University of New York (2008-2010)

Title: Inhibiting brain tumor progression via strategically targeted curcumin.

Ms. Mihwa Na, Department of Chemistry, City College of New York, City University of New York (2011-2017)

Title: Pharmacological Antagonism And The Olfactory Code.

Mr. Sumit Mukerjee, Department of Biochemistry, College of Staten Island, City University of New York (2008-2018)

Title: Strategies involving the food-derived agent curcumin to eliminate brain cancer

Page 5 of 27

McLipkin Fellowship:

Preeti Parhar, (2000).

Title: Left Ventricular Hypertrophy: An Independent Risk Factor For Cardiovascular disease Beena Mathaikutty (2004)

Title: Mycobacterium ulcerans effects on the immune response via quantitative data of TLR2, TLR3, TLR4 and TLR 9

Galina Borodulina, (2006).

Title: Development of a method to measure T-cell activation in vivo

Barry Ladizinski, (2006).

Title: Modified Urinary Nucleosides as Monitors of Metabolism & Disease

Postdoctoral Fellows Trained:

Niharika Nath, PhD Gao J, PhD

Ravinder Kodela, PhD Liu X, PhD

Mitali Chattopadhyay, PhD

Independent Study: The following students have worked in my lab (2002-current) Georges Labaze

Nath N, Labaze G, Rigas B, and Kashfi K. (2004) NO-donating aspirin (NO-ASA) modulates ß-catenin expression in cultured human leukemia cells. Biochem. Biophys. Res. Comm 326, 93-99.

Rashida Vassell

Nath N, Vassell R, Rigas B, and Kashfi K. (2004) NO-ASA strongly inhibits Wnt/ß-catenin signaling in breast cancer MCF-7 cells. Abstract presented at AACR: Third Annual International Conference on Frontiers in Cancer Prevention Research, Seattle, Washington.

Anna Nazarenko

Kashfi K, and Nazarenko A. (2006) Nitric oxide-releasing aspirin suppresses NF-kB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo: An effect through reactive oxygen species. AACR: Fifth Annual International Conference on Frontiers in Cancer Prevention Research, Boston, MA.

Loydine Jacobs Kashfi K, Nath, N, and Jacobs L. (2007) Flurbiprofen benzyl nitrate (FBN) modulates ß-catenin expression and inhibits growth of human epidermoid carcinoma A-431 cells. 10th International Conference on “Eicosanoids & Other Bioactive Lipids in Cancer, Inflammation & Related Diseases”, September 16-19, Montreal, Canada

Galina Borodulina Kashfi K, and Borodulina G. (2007) Flurbiprofen benzylnitrate (FBN) inhibits the growth of various human cancer cells in vitro and prevents intestinal carcinogenesis in Min

Page 6 of 27

(APCMin/+) mice. American Association for Cancer Research, 98th Annual Meeting, Los Angeles CA.

Eleanor Fallon and Arth Patel

Nath N, Fallon EA, Patel AM, Saavedra JE, Keefer LK, and Kashfi K. (2008) JS-K, a Nitric Oxide-Donating Prodrug Inhibits the Growth of Human Colon Cancer Cells: Modulation of ß-catenin/TCF Signaling. American Association for Cancer Research, Annual Meeting, San Diego CA

Liliya Pospishil and Lucyna Z. Cieciura

Kodela R, Chattopadhyay M, Nath N, Cieciura LZ, Pospishil L, Boring D, Crowell JA, and Kashfi K. (2008) Ester-protected hydroxybenzyl phosphates (EHBP) inhibit the growth of various cultured human cancer cells: Evidence of a tissue type-independent effect. AACR: Seventh Annual International Conference on Frontiers in Cancer Prevention Research, Washington, DC. Nath N, Chattopadhyay M, Pospishil L, Cieciura LZ, Saavedra JE, Keefer LK, and Kashfi K. (2008) JS-K, a nitric oxide-donating prodrug, inhibits the growth of leukemic Jurkat cells and modulates β-catenin/TCF signaling. AACR: Seventh Annual International Conference on Frontiers in Cancer Prevention Research, Washington, DC.

Arpine Barsegian, Yosef M Dastagirzada, Cherease R. Street, Diandra E. Nesbitt, Zong Yuan Gan

Dastagirzada MY, Street RC, Nesbitt ED, Gan ZY, Barsegian A, Chattopadhyay M, Kodela R, Boring D, Crowell JA, and Kashfi K. (2011) Hydrogen sulfide-releasing NSAIDs inhibit the growth of various cultured human cancer cell lines: A general property and evidence of a tissue type-independent effect. American Association for Cancer Research, 102nd Annual Meeting, Orlando FL, April 2-6.

Barsegian A, Chattopadhyay M, Kodela R, Boring D, Crowell JA, and Kashfi K. (2011) Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. American Association for Cancer Research, 102nd Annual Meeting, Orlando FL, April 2-6.

Street RC, Chattopadhyay M, Kodela R, Boring D, Crowell JA, and Kashfi K. (2011) Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo. American Association for Cancer Research, 102nd Annual Meeting, Orlando FL, April 2-6.

Nesbitt ED, Chattopadhyay M, Kodela R, Boring D, Crowell JA, and Kashfi K. (2011) Hydrogen sulfide-releasing naproxen inhibits colon cancer cell growth in vitro and in vivo: Effects on the Wnt/β-catenin and NF-κB pathways. American Association for Cancer Research, 102nd Annual Meeting, Orlando FL, April 2-6.

Gan ZY, Chattopadhyay M, Kodela R, Boring D, Crowell JA, and Kashfi K. (2011) Hydrogen sulfide-releasing aspirin inhibits the growth of leukemic Jurkat cells and modulates β-catenin expression. American Association for Cancer Research, 102nd Annual Meeting, Orlando FL, April 2-6.

Gan ZY, Kodela R, Chattopadhyay M, Boring D, Crowell JA, and Kashfi K. (2011) All three positional isomers of acetyloxy benzoic acids are equally potent in inhibiting colon cancer cell growth: Differences in molecular modeling and mode of COX inhibition. American Association for Cancer Research, 102nd Annual Meeting, Orlando FL, April 2-6.

Page 7 of 27

Grants/Extrmurial Funding: Current Therapeutic H2S Delivery: Supramolecular and Enzyme-Triggered Strategies for Controlled Release. NIH R01GM123508 ($1M) J. Mattson (PI), K. Kashfi (Co-Investigator) 2017-2021 Pending: Department of Defense, Breakthrough Award Regulation of estrogen related receptor alpha activity by the kinesin KIF17 in breast epithelial G. Kreitzer (PI), K. Kashfi (Co-PI) 2018-2023 Management of Familial Adenomatous Polyposis with enhanced sulindac NIH R21 K. Kashfi (PI) 2018-2020 Completed: Peroxisome Proliferators and Biomarker Responses PSC-CUNY K. Kashfi (PI) 1999-2001 Pathways to Interdisciplinary Science, Engineering, and Mathematics at CCNY NSF STEP ($600K) D. Gosser (PI), K. Kashfi (Senior Investigator) 2002-2005 Chemoprevention of Pancreatic Cancer with Nitric Oxide-Releasing Aspirin. R01 NIH ($1.25M) B. Rigas (PI), K. Kashfi (Co-PI) 2004-2009 Integration of biological themes into the general chemistry courses at CCNY Howard Hughes Medical Institute Grant ($1M) D. Gosser (PI), K. Kashfi (Investigator) 2005-2009 Evaluation of the Anti-ulcerogenic and Anti-inflammatory Properties of Nitric Oxide-Donating NSAIDs (NONO-NSAIDs). NIH/NCI work assignment ($970K) K. Kashfi (PI) 2008-2009 Preparation and in-vitro testing of specifically substituted phenols to investigate the generation of site directed, selectively reactive quinone methides and their utility for the design of chemopreventive/chemotherapeutic agents. NIH/NCI work assignment ($250K) K. Kashfi (PI) 2007-2011

Page 8 of 27

Institutional Committees: Campus steering committee of the New York City Alliance for Minority Participation in Science, Engineering and Mathematics (AMP), Kingsborough Community College (1997-1999); Member of the Physician Assistant/Assistant Dean Search Committee, Harlam Hospital (2000); Executive Faculty, CUNY Medical School (1999-2014, 2018-2021); Curriculum Committee, CUNY Medical School (Chair, 2000-2006; 2009-2014); Academic Freedom and Faculty Interests, City College of CUNY (2000-2003); Administration, City College of CUNY (2000-2003); Affirmative Action, City College of CUNY (2000-2003). Review Panels: Ad hoc reviewer for the Biochemical Journal, Nutrition and Cancer, Journal of Biochemical Pharmacology, Journal of Pharmacology and Experimental Therapeutics, Cancer Research, Clinical Cancer Research. External Grant Reviewer for “Cancer Research UK”. Editorial Boards: Journal of Biochemical Pharmacology Current Medicinal Chemistry Recent Patents on Anti-Cancer Drug Discovery Invited Presentations:

Kashfi K, and Cook GA. (1992) Effects of Proteases on Carnitine Palmitoyltransferase of Hepatic Mitochondrial Outer Membranes. Federation of American Societies for Experimental Biology (FASEB, Mini symposium).

Kashfi K. (1992) Regulation of Hepatic Mitochondrial Carnitine Palmitoyltransferases,

Department of Biochemistry, University of Alabama. Kashfi K. (1992) Regulation of Hepatic Mitochondrial Carnitine Palmitoyltransferases,

Division of Digestive Diseases, New York Hospital-Cornell Medical Center. Kashfi K, Rimarachin JA, Weksler BB, and Dannenberg AJ. (1993) Differential Regulation of

Glutathione S-Transferase in Rat Aorta Versus Liver. Clinical Research, New York, NY Kashfi K, and Cook GA. (1993) Further Evidence that Malonyl-CoA and Acyl-CoA Sites of

Carnitine Palmitoyltransferase are Distinct, Federation of American Societies for Experimental Biology (FASEB, Mini symposium).

Dannenberg AJ, Yang EK, and Kashfi K. (1993) Dietary Regulation of UDP-

Glucuronosyltransferase. 7th International Workshop on Glucuronidation and the UDP- Glucuronosyltransferases, Pitlochty, Scotland.

Page 9 of 27

Kashfi K, Zhang Y, Yang EK, Talalay P, and Dannenberg AJ. (1995) Anticarcinogenic Organic Isothiocyanates Induce UDP-Glucuronosyltransferase, Federation of American Societies for Experimental Biology (FASEB, Mini symposium).

Kashfi K. (1996) Regulation of Hepatic Mitochondrial Carnitine Palmitoyltransferases,

Seminars in Clinical Research, Rockefeller University, New York, NY.

Kashfi K. (1997) Regulation of Xenobiotic Metabolising Enzymes: A Novel Approach to Cancer Prevention, Seminars in Biochemical Research, Kingsborough Community College, Brooklyn, NY.

Kashfi K. (1998) Regulation of Carnitine Palmitoyltransferase-I: A Limiting Enzyme in Fatty

Acid Metabolism, Medical Department, Brookhaven National Laboratory, Upton, NY. Cook GA, and Kashfi K. (1998) Analysis of the Transmembrane Topology of Hepatic

Mitochondrial Carnitine Palmitoyltransferase-I (CPT-I). The 4th International Fatty Acid Oxidation and Ketogenesis Conference, London England.

Kashfi K. (2000) Regulation of Hepatic Mitochondrial Carnitine Palmitoyltransferase-I, Department of Biochemistry, City College of CUNY, New York, NY.

Kashfi K. (2004) Invited participant by the Division of Cancer Prevention of the National

Cancer Institute in a Cancer Prevention Agent Development meeting addressing Cyclooxygenase, Lipooxygenase, and Nitric Oxide Donating NSAIDs for Chemoprevention. December 13th, Rockville, MD

Kashfi K. (2005) Molecular targets of nitric oxide-donating aspirin in cancer. The Molecular Biology of Colorectal Cancer, Biochemical Society meeting, 10 - 11 March, Bristol, UK

Kashfi K. (2005) Molecular targets of nitric oxide-donating aspirin in cancer prevention. 9th International Conference on “Eicosanoids & Other Bioactive Lipids in Cancer, Inflammation & Related Diseases”, September 11-14, San Francisco, California. Co-Chair of the 9th session.

Kashfi, K. (2006) Molecular Targets of Nitric-oxide-Donating Aspirin in Cancer. Digestive Disease Week, Gastroenterology Division of American Medical Association, May 20-25, Los Angeles, California.

Kashfi K. (2007) The mechanism of action of nitric oxide-releasing aspirin involves quinone methides, carbocations, and oxidative stress: Implications for cancer prevention. 10th International Conference on “Eicosanoids & Other Bioactive Lipids in Cancer, Inflammation & Related Diseases”, September 16-19, Montreal, Canada. Co-Chair of the 11th session.

Kashfi K. (2009) Invited participant by the Division of Cancer Prevention of the National Cancer Institute discussing “NSAIDs and their NO chimeras in cancer prevention”. February 5-6, Rockville, MD.

Kashfi K. (2009) Ester-protected hydroxybenzyl phosphates (EHBP) as bioactivated selectively reactive chemotherapeutic agents. 11th International Conference on “Bioactive Lipids in Cancer, Inflammation & Related Diseases”. October 25–28 Cancun, Mexico.

Kashfi K. (2011) Therapeutic potential of hydrogen sulfide-releasing NSAIDs. 12th International Conference on “Bioactive Lipids in Cancer, Inflammation & Related Diseases”. September 18-21 Seattle, Washington.

Page 10 of 27

Kashfi K. (2012) Nitric oxide-releasing hybrid drugs target cellular processes through S-nitrosylation. First International conference on nitrosylation in oncology and immunology, Ecole Pratique des Hautes Etudes. February 2-3, Dijon, France.

Kashfi K. (2012) Therapeutic potential of new hydrogen sulfide-releasing hybrids. Symposium sponsored by the Comparative and Evolutionary Physiology Section entitled Hydrogen Sulfide: Ecology, Physiology, and Clinical Applications for the Experimental Biology meeting, April 21-25, San Diego, California.

Kashfi K. (2013) NOSH-aspirin for treatment of cancer. 3rd International workshop on nitric oxide in cancer therapy. Queens University School of Medicine, May 31st-June 1st, Kingston, Canada.

Kodela R, Chattopadhyay M, Velázquez-Martínez CA, Kashfi K. (2013) Chemical modulation of the forkhead box M1 (FOXM1) transcription factor in cancer treatment and prevention. Drug Discovery & Therapy World Congress. Boston, MA (USA) June 3rd.

Kashfi K. (2013) Therapeutic potential of nitric oxide- and hydrogen sulfide – releasing non-steroidal anti-inflammatory drugs (NOSH-NSAIDs) in cancer. University of Notre Dame, College of Science, Department of Biological Sciences, Seminar, July 22nd, S Bend, IN.

Kashfi K. (2013) Development and therapeutic potential of NOSH-NSAIDs: A new class of anti-inflammatory pharmaceuticals. David Gaffen School of Medicine, University of California at Los Angeles, Joonson Comprehensive Cancer Center “Leaders in the Field" Seminar, October 14th.

Kashfi K. (2013) Therapeutic potential of NOSH-NSAIDs in cancer. 13th International Conference on “Bioactive Lipids in Cancer, Inflammation & Related Diseases”. November 3-6, San Juan, Puerto Rico.

Kashfi K. (2014) NO-H2S (NOSH) releasing chimeras as a multifaceted approach to cancer

therapy. Symposium: NO, CO and H2S: Toxic Gases, Gasotransmitters and Therapeutic Targets. The American Physiological Society; Experimental Biology meeting, April 27, San Diego, CA.

Nia KV, Chattopadhyay M, Metkar S, Kodela R, Kvint S, and Kashfi K. (2014) Targeting NF-κB, FoxM1, and p53 in pancreatic cancer with NOSH-aspirin. Digestive Disease Week, May 4-6 Chicago, IL.

Kashfi K. (2014) Development and therapeutic potential of nitric oxide- and hydrogen sulfide-

releasing non-steroidal anti-inflammatory drugs (NOSH-NSAIDs): A new class of anti-inflammatory pharmaceuticals. Department of Agricultural Sciences, Biotechnology and Food Science, Cyprus University of Technology, November 25th, Limassol, Cyprus.

Kashfi K. (2015) NOSH-aspirin a designer nitric oxide- and hydrogen sulfide-releasing hybrid

for treatment of cancer: Rational and Promise. Department of Biochemistry and Molecular Biology, New York Medical College, January 21st, Valhalla, NY.

Kashfi K. (2015) Utility of nitric oxide and hydrogen sulfide-releasing chimeras as anticancer

agents. IV International Conference “Nitric Oxide in Cancer”. Institute of Biomedicine of Sevilla (IBIS), March 13-14, Sevilla, Spain.

Page 11 of 27

Kashfi K. (2015) Molecular targets of NOSH-aspirin in cancer. 14th International Conference on “Bioactive Lipids in Cancer, Inflammation & Related Diseases”. July 12-15, Budapest, Hungary.

Kashfi K. (2015) Development and Therapeutic Potential of NOSH-NSAIDs: A New Class of

Anti-inflammatory Pharmaceuticals. Department of Chemistry, Brooklyn College, City University of New York. October 30th.

Kashfi K. (2016) Development and therapeutic potential of NOSH-NSAIDs: A new class of

anti-inflammatory pharmaceuticals that release nitric oxide and hydrogen sulfide. Biochemical Society Irish Area Section, “Inflammatory diseases - mechanisms and clinical perspectives”. November 3-4, Maynooth University, Ireland.

Kashfi K. (2017) Molecular targets of NOSH-aspirin in a xenograft mouse model of ER(-)

breast cancer. 5th International workshop on nitric oxide and cancer, 22-24 March, Bologna, Italy.

Kashfi K. (2017) Targeting NF-κB, FoxM1, and p53 in pancreatic cancer with NOSH-aspirin.

15th International Conference on “Bioactive Lipids in Cancer, Inflammation & Related Diseases”. October 22-25, Puerto Vallarta, Mexico.

Kashfi K. (2018) NOSH-aspirin a chimera that releases NO and H2S modulates redox-

sensitive signaling pathways in cancer cells. 20th International Conference on Oxidative Stress, Redox Homeostasis and Antioxidants – July 6-7, Paris, France.

Kashfi K. (2018) Building better and safer NSAIDs: Development and therapeutic potential of

hybrids that release nitric oxide and hydrogen sulfide. 3rd International Conference on Cancer Research & Targeted Therapy. August 6-8, London, England.

Kashfi K. (2018) Nitric oxide and cancer: To inhibit or to induce iNOS – That is the question?

Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory-related Disorders Accademia dei Fisiocritici, October 4-5, Siena, Italy.

Page 12 of 27

Specialities by Training or Experience: Pharmacology, Physiology, Biochemistry, Medicinal Chemistry (drug design and synthesis), Polymer: chemistry, physics, processing & engineering; General analytical techniques (HPLC, TLC, GC, UV, IR), Radio-ligand binding, Small animal surgery, Electrophoresis, Western and Northern blotting, Tissue culture, Protein purification, Lymphocytes isolation and purification, Familiar with some molecular biology techniques (DNA gels, PCR, gel shift assays), Microradiography, Immunohistochemistry, Cell fractionation, Membrane isolation, Enzyme kinetics, Computer skills. Research Interests:

1. The biology of colon, pancreatic, and breast cancers and their chemoprevention.

2. Regulation of lipid metabolism including eicosanoids. Patents: Khosrow Kashfi. 20050182134 - Compounds and compositions for treating

dysproliferative diseases, and methods of use thereof. Granted 2009

Khosrow Kashfi & Ravinder Kodela. NO- and H2S-releasing compounds. WO 2013025790A2

Khosrow Kashfi, Ravinder Kodela, Mitali Chattopadhyay. NSAIDs derivatives and uses thereof. WO 2014/124208 A1

Khosrow Kashfi & Vassilis Fotopoulos. Method of Priming Plants Against Abiotic Stress Factors. WO2015/123273 A1

Bibliography: H-index: 35, i10-index: 64 A. Full Manuscripts 1. Kashfi K, Weakley LJ, and Cook GA. (1988) The Effects of Diabetes on the Carnitine Palmitoyltransferase of Isolated Hepatic Mitochondrial Outer Membranes. Biochem. Soc. Trans. 16, 1010-1011. 2. Kashfi K, Israel M, Sweatman TW, Seshadrei R, and Cook GA. (1990) Inhibition of

Mitochondrial Carnitine Palmitoyltransferases by Adriamycin and Adriamycin Analogues. Biochem. Pharma. 40, 1441-1448.

3. Kashfi K, Dory L, and Cook GA. (1991) Effects of Cholesterol Loading of Mouse Macrophages on Carnitine Palmitoyltransferase Activity and Sensitivity to Inhibition by Malonyl-CoA. Biochem. Biophys. Res. Comm. 177, 1121-1126.

Page 13 of 27

4. Kashfi K, and Cook GA. (1991) Malonyl-CoA Inhibits Proteolysis of Carnitine Palmitoyltransferase. Biochem. Biophys. Res. Comm. 178, 600-605. 5. Kashfi K, and Cook GA. (1992) Proteinase Treatment of Intact Hepatic Mitochondria has Differential Effects on Inhibition of Carnitine Palmitoyltansferase by Different Inhibitors. Biochem. J. 282, 909-914. 6. Kashfi K, and Cook GA. (1993) Inhibition of Carnitine Palmitoyltransferase of the Hepatic

Mitochondrial Outer Membrane (CPT-I) by 2-Bromopalmitoyl-CoA. Biochem. Soc. Trans. 21, 503S.

7. Kashfi K, Mynatt RL, and Cook GA. (1994) Hepatic Carnitine Palmitoyltransferase-I Has Two

Independent Inhibitory Binding Sites for Regulation of Fatty Acid Oxidation. Biochim. Biophys. Acta. 1212, 245-252.

8. Cook GA, Mynatt RL, and Kashfi K. (1994) Yonetani-Theorell Analysis of Hepatic Carnitine Palmitoyltransferase-I Inhibition Indicates Two Distinct Inhibitory Binding Sites. J. Biol. Chem. 269, 8803-8807. 9. Kashfi K, Rimarachin JA, Weksler BB, and Dannenberg AJ. (1994) Differential Induction of

Glutathione S-Transferases in the Rat Aorta Versus Liver. Biochem. Pharma. 47, 1903-1907.

10. Kashfi K, Yang EK, Roy Chowdhury J, Roy Chowdhury N, and Dannenberg AJ. (1994)

Regulation of Uridine Diphosphate Glucuronosyltransferase Expression by Phenolic Antioxidants. Cancer Res. 54, 5856-5859.

11. Makar TK, Hungund BL, Cook GA, Kashfi K, and Cooper AJL. (1995) Lipid Metabolism and

Membrane Composition are Altered in the Brains of Type II Diabetic Mice. J. Neurochem. 64, 2159-2168.

12. Kashfi K, Cagen L, and Cook GA. (1995) Diabetes and Proteolysis: Effects on

Carnitine Palmitoyltransferase-I and Malonyl-CoA Binding. Lipids 30, 383-388. 13. Kashfi K, and Cook GA. (1995) Temperature Effects on Malonyl-CoA Inhibition of Carnitine

Palmitoyltransferase-I. Biochim. Biophys. Acta. 1257, 133-139 14. Kashfi K, and Dannenberg AJ. (1995) Omeprazole Co-Induces Multiple Xenobiotic Metabolizing Enzymes in the Rat. Anna. New York Acad. Sci. 768, 237-242 15. Yang EK, Kashfi K, Roy Chowdhury J, Roy Chowdhury N, and Dannenberg AJ. (1995)

Phenolic Antioxidants Induce UDP-Glucuronosyltransferase in Rat Liver. Anna. New York Acad. Sci. 768, 231-236

16. Park EA, Mynatt RL, Cook GA, and Kashfi K. (1995) Insulin Regulates Enzyme

Activity, Malonyl-CoA Sensitivity and mRNA Abundance of Hepatic Carnitine Palmitoyltransferase-I. Biochem. J. 310, 853-858 17. Kashfi K, McDougall CJ, and Dannenberg AJ. (1995) Comparative Effects of Omeprazole on

Xenobiotic Metabolizing Enzymes in the Rat and Human. Clin. Pharma. Ther. 58, 625-630

Page 14 of 27

18. Bortuzzo C, Hanif R, Kashfi K, Staiano-Coico L, Shiff SJ, and Rigas B. (1996) The Effect of Leukotrienes B and Selected HETEs on the Proliferation of Colon Cancer Cells. Biochem. Biophys. Acta. 1300, 240-246

19. Aliprandis ET, Merritt GA, Prada F, Rigas B, and Kashfi K. (1997) Fenretinide Inhibits

Phorbol Ester-induced Cyclooxygenase-2 Expression in Human Colon Adenocarcinoma Cells. Biochem. Soc. Trans. 25, 457S

20. Kashfi K. and Cook GA. (1999) Analysis of the Transmembrane Topology of Hepatic

Mitochondrial Carnitine Palmitoyltransferase-I. Adv Exp Med Biol. 466, 27-42. 21. Merritt GA, Aliprandis ET, Prada F, Rigas B, and Kashfi K. (2001) The Retinoid Fenretinide

InhibitsProliferation and Downregulates Cyclooxygenase-2 Gene Expression in Human Colon Adenocarcinoma Cell Lines. Cancer Lett., 164, 15-23.

22. Visvanathan K, Charles A, Bannan J, Pugach P, Kashfi K, and Zabriskie JB.(2001) Inhibition

of Bacterial Superantigens by Peptides and Antibodies. Infection & Immunity 69, 875-884. 23. Kaza CS, Kashfi K, and Rigas B. (2002) Colon Cancer Prevention with NO-Releasing

NSAIDs. Prost. & Other Lipid Mediat. 67, 107-120. 24. Kashfi K, Ryann Y, Qiao LL, Williams JL, Chen J, Del Soldato P, Traganos F, and Rigas B.

(2002) Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J Pharmacol Exp Ther (Cover Issue). 303, 1273-82.

25. Williams J, Nath N, Chen J, Hundley T, Gao J, Kopelovich L, Kashfi K, and Rigas B. (2003)

Growth Inhibition of Human Colon Cancer Cells by Nitric Oxide (NO)-Donating Aspirin is Associated with Cyclooxygenase-2 Induction and ß-Catenin/T-Cell Factor Signaling, Nuclear Factor-kB and NO Synthase 2 Inhibition: Implications for Chemoprevention. Cancer Res. 63, 7613-7618.

26. Nath N, Kashfi K, Chen J and Rigas B. (2003) NO-donating aspirin inhibits beta-catenin

/TCF signaling in SW480 colon cancer cells more potently than aspirin by disrupting the nuclear beta-catenin–TCF association: Relevance to colon cancer chemoprevention. Proc. Natl. Aca. Sci., USA 100, 12584-12589.

27. Williams JL, Kashfi K, Ouyang N, del Soldato P, Kopelovich L, and Rigas B. (2004) NO-

Donating Aspirin Inhibits Intestinal Carcinogenesis in MIN (APC Min/+) Mice. Biochem. Biophys. Res. Comm 313, 784-788.

28. Yeh RK, Chen J, Williams JL, Baluch M, Hundley TR, Rosenbaum RE, Kalala S, Traganos F,

Benardini F, del Soldato P, Kashfi K, and Rigas B. (2004) NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: A general pharmacological property. Biochem. Pharmacol. 67, 2197-2205.

29. Rigas B, and Kashfi K. (2004) Nitric oxide–donating NSAIDs as agents for cancer

prevention. Trends in Mol. Med. 10, 324-330.

Page 15 of 27

30. Nath N, Labaze G, Rigas B, and Kashfi K. (2004) NO-donating aspirin (NO-ASA) modulates ß-catenin expression in cultured human leukemia cells. Biochem. Biophys. Res. Comm 326, 93-99.

31. Kashfi K, Borgo S, Williams JL, Chen J, Glekas A, Traganos F, Benedini F, del Soldato P,

Rigas B. (2005) Positional isomerism markedly affects the growth inhibition of colon cancer cells by NO-releasing aspirin: A structure-activity study in vitro and in vivo. J Pharmacol Exp Ther 312, 978-988.

32. Gao J, Kashfi K, and Rigas B. (2005) In vitro metabolism of NO-donating aspirin: The effect

of positional isomerism. J Pharmacol Exp Ther 312, 989-997. 33. Rigas B, and Kashfi K. (2005) Cancer prevention: A new era beyond COX-2. J Pharmacol

Exp Ther (Perspectives in Pharmacology, July cover issue) 314, 1-8. 34. Kashfi K, and Rigas B. (2005) Non-COX-2 targets and cancer: Expanding the molecular

target repertoire of chemoprevention. Biochem. Pharmacol. (commentary) 70, 969-986. 35. Kashfi K, and Rigas B. (2005) Molecular targets of nitric oxide-donating aspirin in cancer.

Biochem. Soc. Trans 33, part 4, 701-704. 36. Kashfi K, and Rigas B. (2005) Is COX-2 a “collateral” target in cancer prevention? Biochem.

Soc. Trans 33, part 4, 724-727. 37. Spiegel A, Hundley TR, Chen J, Gao J, Ouyang N, Williams JL, Liu X, Go MF, Tsioulias G,

Kashfi K, and Rigas B. (2005) NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthease in HT-29 human colon cancer cells. Biochem. Pharmacol. 70, 993-1000.

38. Savle PS, Neptune NE, Yang Y, Rouden JH, Kite BL, Sugandhi EW, Macri RV, Kashfi K,

and Gandour RD. (2005) Comparison of (+)- and (-)-Hemipalmitoylcarnitinium as Inhibitors of Hepatic Mitochondrial Carnitine Palmitoyltransferases in Diabetic Rats. Med. Chem. 5, 445-453.

39. Ouyang N, Williams JL, Tsioulias G, Gao J, Latropoulos M, Kopelovich L, Kashfi K, and

Rigas B. (2006) NO-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res. 66, 4503-4511.

40. Gao J, Kashfi K, Liu X, and Rigas B. (2006) NO-donating aspirin induces phase II enzymes

in vitro and in vivo. Carcinogenesis 27, 803-810. 41. Kashfi K, and Rigas B. (2007) The mechanism of action of nitric oxide-donating aspirin.

Biochem. Biophys. Res. Comm. 358, 1096-1101. 42. Nath N, Vassell R, Chattopadhyay M, Kogan M, Kashfi K. (2009) Nitro-aspirin inhibits MCF-

7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling. Biochem Pharmacol. 78,1298-304.

43. Kashfi K. (2009) Anti-Inflammatory Agents as Cancer Therapeutics. Adv in Pharmacol, 57,

31-89.

Page 16 of 27

44. Nath N, Chattopadhyay M, Kodela R, Vlismas P, Boring D, Crowell JA, and Kashfi K. (2010) Modulation of stress genes expression profile by nitric oxide-releasing aspirin in Jurkat T leukemia cells. Biochem Pharmacol. 79, 1759-71.

45. Nath N, Chattopadhyay M, Pospishil L, Cieciura LZ, Goswami S, Kodela R, Saavedra JE,

Larry K. Keefer LK, and Kashfi K. (2010) JS-K, a nitric oxide-releasing prodrug, modulates β-catenin/TCF signaling in leukemic Jurkat cells: Evidence of an S-nitrosylated mechanism. Biochem Pharmacol. 80, 1641-9.

46. Chattopadhyay M, Velazquez CV, Pruski A, Nia KV, Abdelatif K, Keefer LK, and Kashfi K. (2010) Comparison between 3-Nitrooxyphenyl acetylsalicylate (NOASA) and O2- (acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as Safe Anti-Inflammatory, Analgesic, Antipyretic, Antioxidant Prodrugs. J Pharmacol Exp Ther. 335, 443-50. 47. Chattopadhyay M, Goswami S, Rodes DB, Kodela R, Velazquez CA, Boring D, Crowell JA,

and Kashfi K. (2010) Nitric oxide-releasing non-steroidal anti-inflammatory suppress NF-κB signaling in vitro and in vivo through S-nitrosylation. Cancer Lett. 298, 204-11.

48. Kashfi K, Mynatt RL, Park EA, Cook GA. (2011) Membrane Microenvironment Regulation of

Carnitine Palmitoyltranferases I and II. Biochem. Soc. Trans. 39, 833-7. 49. Kodela R, Chattopadhyay M, Nath N, Cieciura LZ, Pospishill L, Boring D, Crowell JA, and

Kashfi K. (2011) Synthesis and biological activity of acetyl-protected hydroxybenzyl diethyl phosphates (EHBP) as potential chemotherapeutic agents. Bioorg. Med. Chem. Lett. 21, 7146-7150.

50. Jain S, El Gendy MAM, Kashfi K, Jurasz P, and Velázquez CA. (2012) Nitric oxide release is

not required to decrease the ulcerogenic profile of NSAIDs. J. Med. Chem. 55, 688-696. 51. Chattopadhyay M, Kodela R, Nath N, Dastagirzada YM, Velázquez-Martínez CA, Boring D,

and Kashfi K. (2012) Hydrogen sulfide-releasing NSAIDs inhibit the growth of cultured human cancer cells: A general property and evidence of a tissue type-independent effect. Biochem Pharmacol. 83, 715-722.

52. Chattopadhyay M, Kodela R, Nath N, Barsegian A, Boring D, and Kashfi K. (2012)

Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. Biochem Pharmacol. 83, 723-732.

53. Chattopadhyay M, Kodela R, Nath N, Street CA, Velázquez-Martínez CA, Boring D, and

Kashfi K. (2012) Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo. Biochem Pharmacol. 83, 733-740.

54. Kodela R, Chattopadhyay M, and Kashfi K. (2012) NOSH-aspirin: A novel nitric oxide-

hydrogen sulfide-releasing hybrid: A new class of anti-inflammatory pharmaceuticals. ACS Med. Chem. Lett. 3, 257–262.

55. Chattopadhyay M, Kodela R, Olson KR, and Kashfi K. (2012) NOSH-aspirin (NBS 1120), a

novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochem. Biophys. Res. Comm. 419, 523-528.

Page 17 of 27

56. Kashfi K. (2012) Nitric Oxide-Releasing Hybrid Drugs Target Cellular Processes Through S-Nitrosylation. For Immunopathol Dis Therap 3(2), 97-109.

57. Kashfi K and Olson KR. (2013) Biology and therapeutic potential of hydrogen sulfide and

hydrogen sulfide-releasing chimeras Biochem Pharmacol special issue Guest Editor 85, 689-703.

58. Kashfi K. (2013) Dysfunctional cell signaling dynamics in oncology: Diagnostic, prognostic

and treatment opportunities. Preface. Biochem Pharmacol. Guest Editor 85, 595-596. 59. Kodela R, Chattopadhyay M, Goswami S, Gan ZY, Rao PNP, Nia, KV, Velázquez-Martínez

CA, and Kashfi K. (2013) All three positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: Differences in mode of COX inhibition. J Pharmacol Exp Ther. 345, 85-94.

60. Nath N, Liu X, Jacobs L, and Kashfi K. (2013) Flurbiprofen benzylnitrate (NBS-242) inhibits

the growth of A-431 human epidermoid carcinoma cells and targets β-catenin. Drug Des Devel Ther. 7, 389-96.

61. Chattopadhyay M, Nath N, Kodela R, Gan ZY, and Kashfi K. (2013) Hydrogen sulfide-

releasing aspirin inhibits the growth of leukemic Jurkat cells and modulates β-catenin expression. Leukemia Res. 37 (10), 1302-8.

62. Lee M, McGeer E, Kodela R, Kashfi K, and McGeer PL. (2013) NOSH-aspirin (NBS-1120) a novel nitric oxide and hydrogen sulfide releasing hybrid attenuates neuroinflammation induced by microglial and astrocytic activation: A new candidate for treatment of neurodegenerative disorders. GLIA 61 (10), 1724-34. 63. Kodela R, Chattopadhyay M, and Kashfi K. (2013) Synthesis and biological activity of NOSH-naproxen (AVT-219) and NOSH-sulindac (AVT-18A) as potent anti-inflammatory agents with chemotherapeutic potential. Med Chem Commm 4 (11), 1472–1481. 64. Kashfi K. (2014) Anti-cancer activity of new hydrogen sulfide-donating hybrids. Antioxid

Redox Signal. 10, 831-46 65. Fonseca MD, Cunha FQ, Kashfi K, Cunha TM. (2015) NOSH-Aspirin (NBS-1120), a dual

nitric oxide and hydrogen sulfide-releasing hybrid, reduces inflammatory pain. Pharmacol Res Perspect. Jun;3(3):e00133, 1-8

66. Kodela R, Nath N, Chattopadhyay M, Nesbitt DE, Velázquez-Martínez CA, and Kashfi K.

(2015) Hydrogen sulfide-releasing naproxen suppresses colon cancer cell growth and inhibits NF-κB signaling. Drug Des Devel Ther. 9, 4873–4882

67. Nath N, Chattopadhyay M, Rodes DB, Nazarenko A, Kodela R, and Kashfi K. (2015) Nitric

oxide-releasing aspirin suppresses NF-kB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. Molecules 20 (7), 12481-12499.

68. Kashfi K, Chattopadhyay M, Kodela R. (2015) NOSH-sulindac (AVT-18A) is a novel nitric

oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties. Redox Biol. 6, 287-296.

Page 18 of 27

69. Vannini F, Chattopadhyay M, Kodela R, Rao PPN and Kashfi K. (2015) Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-Aspirin: COX inhibition and modeling. Redox Biol. 6, 318-325

70. Vannini F, MacKessack-Leitch AC, Eschbach EK, Chattopadhyay M, Kodela R, and Kashfi

K. (2015) Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid. Bioorg. Med. Chem. Lett. 25, 4677-4682.

71. Vannini F, Kashfi K, and Nath N. (2015) The dual role of iNOS in cancer. Redox Biol. 6, 334-

343. 72. Kodela R, Chattopadhyay M, Velázquez-Martínez CA, and Kashfi K. (2015) NOSH-aspirin

(NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications. Biochem Pharmacol. 98(4):564-72.

73. Chattopadhyay M, Kodela R, Duvalsaint PL, and Kashfi K. (2016) Gastrointestinal safety,

chemotherapeutic potential, and classic pharmacological profile of NOSH-naproxen (AVT-219) a dual NO and H2S-releasing hybrid. Pharmacol Res Perspect. Mar 4;4(2):e00224, 1-15, doi: 10.1002/prp2.224

74. Gheibi S, Kashfi K, and Ghasemi A. (2017) A practical guide for induction of type-2 diabetes

in rat: Incorporating a high-fat diet and streptozotocin. Biomedicine & Pharmacotherapy 95:605-613. doi: 10.1016/j.biopha.2017.08.098

75. Gheibi S, Jeddi S, Kashfi K, and Ghasemi A. (2018) Regulation of vascular tone

homeostasis by NO and H2S: Implications in hypertension. Biochem Pharmacol. 149, 42-59. doi: 10.1016/j.bcp.2018.01.017

76. Kashfi K. (2018) The dichotomous role of H2S in cancer cell biology? Déjà vu all over again.

Biochem Pharmacol. 149, 205-223. https://doi.org/10.1016/j.bcp.2018.01.042 77. Kashfi K. (2018) The role of hydrogen sulfide in health and disease. Editorial, Biochem

Pharmacol. 149, 1-4. https://doi.org/10.1016/j.bcp.2018.02.030 78. Bakhtiarzadeh F, Siavoshi F, Gheibi S, Kashfi K, Samadi R, Jeddi S, Ghasemi A. (2018)

Effects of long-term oral nitrate administration on adiposity in normal adult female rats. Life Sci. S0024-3205(18)30478-8. doi: 10.1016/j.lfs.2018.08.032

79. Gheibi A, Khanahmad H, Kashfi K, Sarmadi M, Khorramizade MR. (2018) Development of

new generation of vaccines for Brucella abortus. Heliyon 4 e01079. doi:10.1016/j.heliyon.2018.e01079

80. Gheibi S, Jeddi S, Kashfi K*, Ghasemi A. (2019) Effects of hydrogen sulfide on carbohydrate

metabolism in obese type-2 diabetic rats. Molecules 24(1), 190; doi.org/10.3390/molecules24010190 *Co-corresponding author

81. Jeddi S, Gholamia H, Gheibi S, Kashfi K*, Ghasemi A. (2019) Altered gene expression of

hydrogen sulfide-producing enzymes in hyperthyroid rats. J Cell Physiol. (in press) doi.org/10.1002/jcp.28426 *Co-corresponding author

Page 19 of 27

82. Gheibi S, Mahmoodzadeh A, Kashfi K, Jeddi S, Ghasemi A. (2019) Data extraction from graphs using Adobe Photoshop: Applications for meta-analyses. Submitted

83. Chattopadhyay M, Kodela R, LeCao TT, Santiago G, Nath N and Kashfi K. (2019) NOSH-

aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS. Submitted

84. Gheibi S, Jeddi S, Carlstrom M, Kashfi K*, Ghasemi A. (2019) Hydrogen sulfide potentiates

the favourable metabolic effects of inorganic nitrite in type 2 diabetic rats. Nitric Oxide (under revision) *Co-corresponding author

85. Salehi S, Kashfi K, Manaheji H, Haghparast A. (2019) Chemical stimulation of the lateral

hypothalamus induces antiallodynic and antithermal hyperalgesic effects in animal model of neuropathic pain: Involvement of orexin receptors in the spinal cord. Submitted

B. Books “Cell Signaling and Molecular Targets in Cancer", (2011) Chatterjee M and Kashfi K Editors,

Publisher, Springer USA. C. Book Chapters 1. Kashfi K, and Cook GA. (1999) Topology of Hepatic Mitochondrial Carnitine

Palmitoyltransferase-I. In "Current Views of Fatty Acid Oxidation and Ketogenesis: From Organelles to Point Mutations". Series: Advances in Experimental Medicine and Biology. Vol 466, pp27-42. P.A. Quant and S. Eaton, Eds., Kluwer Academic/Plenum Publishers.

2. Neptune NE, Savle PS, Nam IU, Gandour RD, and Kashfi K. (2001) Comparative Effects of

Hemipalmitoylcarnitinium (HPC) Stereoisomers on Hepatic Mitochondrial Carnitine Palmitoyltransferases (CPT) in the Diabetic Rat. In “New Avenues of Research in Fatty Acid Oxidation and Ketone Body Metabolism” pp5-9. P.A. Quant and S. Eaton, Eds.,FAOXK Press England.

3. Kashfi K. (2009) Anti-Inflammatory Agents as Cancer Therapeutics. In: CONTEMPORARY

ASPECTS OF BIOMEDICAL RESEARCH: DRUG DISCOVERY. Edited by SJ Enna and M Williams, Elsevier. Advances in Pharmacology, Volume 57, 2009, Pages 31-89

4. Kashfi K and Duvalsaint PL. (2017) Nitric Oxide Donors and Therapeutic Applications in

Cancer. In: Nitric Oxide Donors: Novel Biomedical Applications and Perspectives. Edited by Amedea Barozzi Seabra, Elsevier.

5. Kashfi K and Esmaili M. (2017) NO-H2S releasing chimeras as a multifaceted approach to

cancer therapy. In: Cancer Sensitizing Agents for Chemotherapy--NITRIC OXIDE (DONOR/INDUCED) IN CHEMOSENSITIZATION, Volume 1. Edited by Benjamin Bonavida, Elsevier, Academic Press.

Page 20 of 27

6. Scicinski J and Kashfi K. (2018) Cancer and Beyond: Discovery and development of NO-releasing therapeutics. In: Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory-related Disorders. Edited by Benjamin Bonavida & Lucia Morbidelli, Elsevier, Academic Press.

7. Kashfi K and Vannini F. (2018) Nitric Oxide and Cancer: To Inhibit or To Induce iNOS – That

is the Question? In: Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory-related Disorders. Edited by Benjamin Bonavida & Lucia Morbidelli, Elsevier, Academic Press.

D. Abstracts 1. Cook GA, Kashfi K, and Weakley LJ. (1988) Effects of Fasting on Carnitine

Palmitoyltransferase (CPT) from the Mitochondrial Outer Membrane. FASEB J. 2: A1035. 2. Cook GA, Weakley LJ, and Kashfi K. (1988) Regulatory Properties of Carnitine Palmitoyltransferase from the Hepatic Mitochondrial Outer Membranes. The 14th International Congress of Biochemistry, Prague. 3. Kashfi K, and Cook GA. (1991) Effects of Proteases on Overt Mitochondrial

Carnitine Palmitoyltransferase (CPT-I) Activity and Inhibition by Different Inhibitors. FASEB J. 5: A827.

4. Kashfi K, and Cook GA. (1991) Malonyl-CoA Regulates Proteolysis of Carnitine Palmitoyltransferase. The Pharmacologist 33:200. 5. Kashfi K, and Cook GA. (1992) Effects of Proteases on Carnitine Palmitoyltransferase of Hepatic Mitochondrial Outer Membranes. FASEB J. 6:A1368 (Mini symposium). 6. Kashfi K, and Cook GA. (1993) Further Evidence that Malonyl-CoA and Acyl-CoA Sites of Carnitine Palmitoyltransferase are Distinct. FASEB J. 7: A615. 7. Kashfi K, Rimarachin JA, Weksler BB, and Dannenberg AJ. (1993) Differential Regulation of Glutathione S-Transferase in Rat Aorta Versus Liver. Clinical Research 41 (3):A595. 8. Yang EK, Kashfi K, Roy Chowdhury N, Roy Chowdury J, and Dannenberg AJ. (1993) Effect of Dietary Composition on Bilirubin-UDP-Glucuronosyltransferase. Hepatology 18 (4):A127. 9. Dannenberg AJ, Yang EK, and Kashfi K. (1993) Dietary Regulation of UDP-

Glucuronosyltransferase. In: 7th International Workshop on Glucuronidation and the UDP-Glucuronosyltransferases, Page 19, Pitlochty, Scotland.

10. Kashfi K, Rimarachin JA, Weksler BB, and Dannenberg AJ. (1994) Effect of a Fat Free Diet

on Glutathione S-Transferase (GST) in the Rat Aorta. FASEB J. 8: A1207 11. Kashfi K, Yang EK, Roy Chowdhury N, Roy Chowdury J, and Dannenberg AJ. (1994)

Regulation of UDP-Glucuronosyltransferase Gene Expression by Antioxidants. Gastroenterology 106: A916

Page 21 of 27

12. Kashfi K, and Dannenberg AJ. (1994) Omeprazole Co-induces Multiple Xenobiotic Metabolizing Enzymes in Rat Liver. Hepatology 20 (4):A187. 13. Ramonetti J, Kashfi K, Yang EK, and Dannenberg AJ. (1994) Effect of Dietary Lipid

Saturation on Xenobiotic Metabolizing Enzymes in the Liver. Hepatology 20 (4):A389. 14. Kashfi K, Zhang Y, Yang EK, Talalay P, and Dannenberg AJ. (1995) Anticarcinogenic

Organic Isothiocyanates Induce UDP-Glucuronosyltransferase. FASEB J. 9: A868 (Mini symposium)

15. Kashfi K, Yang EK, Zhang Y, Talalay P, and Dannenberg AJ. (1995) Anticarcinogenic

Organic Isothiocyanates Coordinately Induce Multiple Xenobiotic Metabolizing Enzymes in Liver and Small Intestine. Gastroenterology 108: A129

16. Kashfi K, McDougall CJ, and Dannenberg AJ. (1995) Comparative Effects of Omeprazole on

Xenobiotic Metabolizing Enzymes in the Rat and Human Small Intestine. Gastroenterology 108: A488

17. Bortuzzo, C., Hanif, R., Kashfi, K., Staiano-Coico, L., Shiff, S.J., and Rigas, B. (1996) The

Effect of Leukotrienes B and Selected HETEs on the Proliferation of Colon Cancer Cells. Gastroenterology 110 (4 Suppl): A494

18. Kashfi K, Shiff SJ, and Rigas B. (1996) Evidence for Leukotriene B4 receptors in Human

Colon Cancer Cells. Gastroenterology 110 (4 Suppl): A540 19. Kashfi K, Shiff SJ, and Rigas B. (1996) Evidence that Human Epithelial Cells Express Leukotriene Receptors. FASEB J. 10:A400 20. Yang EK, Seow HA, Kashfi K, McDougall CJ, and Dannenberg AJ. (1996) Proton Pump

Inhibitors Induce UDP-Glucuronosyltransferase in the Rat and Human. Proceedings of the 8th International Workshop on Glucuronidation, Iowa City.

21. Dannenberg AJ, Kashfi K, Roy Chowdhury N, Roy Chowdury J, and Yang EK. (1996)

Dirtary Regulation of UDP-Glucuronosyltransferase (UGT): An Approach to Cancer Prevention. Proceedings of the 8th International Workshop on Glucuronidation, Iowa City.

22. Cook GA, and Kashfi K. (1998) Analysis of the Transmembrane Topology of Hepatic Mitochondrial Carnitine Palmitoyltransferase-I (CPT-I). The 4th International Fatty Acid Oxidation and Ketogenesis Conference, London England. 23. Cacciola SA, Cohen LA, and Kashfi K. (1999) Lycopene Inhibits Proliferation and Regulates Cyclooxygenase-2 Gene Expression in Neoplastic Rat Mammary Epithelial Cells. FASEB J. 13:A551 24. Nath N, Kashfi K, and Rigas B. (2003) NO-donating Aspirin Inhibits the Wnt Signaling

Patheay More Potently than Traditional Aspirin. Am. Assoc. Can. Res. Toronto Canada. A:5597

25. Kashfi K, Yeh R, Williams JL, Hundly TR, Chen J, and Rigas B. (2003) NO-donating

NSAIDs Inhibit the Growth of Cultured Human Colon Cancer Cells More Effectively than Traditional NSAIDs: A General Property. Am. Assoc. Can. Res. Toronto Canada. A:2679

Page 22 of 27

26. Ouyang N, Williams JL, Gao J, Latropoulos MJ, Tsioulias GL, Kopelovich L, Kashfi K, and

Rigas B. (2004) NO-releasing aspirin prevents pancreatic cancer in the hamster and modulates cell kinetics, NF-kB and COX-2 expression. AACR: Third Annual International Conference on Frontiers in Cancer Prevention Research, Seattle, Washington.

27. Spiegel A, Hundley TR, Chen J, Gao J, Ouyang N, Williams JL, Xiaoping X, Go MF,

Tsioulias GL, Kashfi K, and Rigas B. (2004) NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells. AACR: Third Annual International Conference on Frontiers in Cancer Prevention Research, Seattle, Washington.

28. Williams JL, Kashfi K, Ouyang N, Liu X, Kopelovich L and Rigas B. (2004) NO-releasing aspirin prevents pancreatic cancer in the hamster and NO-donating aspirin inhibits intestinal carcinogenesis in min (Apcmin/+) mice. AACR: Third Annual International Conference on Frontiers in Cancer Prevention Research, Seattle, Washington.

29. Kashfi K, Borgo S, Williams JL, Chen J, Glekas A, Traganos F, Benedini F, del Soldato P, and Rigas B. (2004) Positional isomerism markedly affects the growth inhibition of colon cancer cells by NO-releasing aspirin: A structure-activity study in vitro and in vivo. AACR: Third Annual International Conference on Frontiers in Cancer Prevention Research, Seattle, Washington.

30. Gao J, Kashfi K, and Rigas B. (2004) In vitro metabolism of NO-donating aspirin: The effect of positional isomerism. AACR: Third Annual International Conference on Frontiers in Cancer Prevention Research, Seattle, Washington.

31. Nath N, Vassell R, Rigas B, and Kashfi K. (2004) NO-ASA strongly inhibits Wnt/ß-catenin signaling in breast cancer MCF-7 cells. AACR: Third Annual International Conference on Frontiers in Cancer Prevention Research, Seattle, Washington.

32. Nath N, Labaze G, Rigas B, and Kashfi K. (2004) NO-donating aspirin (NO-ASA) modulates ß-catenin expression in cultured human leukemia cells. AACR: Third Annual International Conference on Frontiers in Cancer Prevention Research, Seattle, Washington

33. Kashfi K, and Rigas B. (2005) Molecular targets of nitric oxide-donating aspirin (NO-ASA) in

cancer. Biochemical Society Focused Meeting, Bristol, England. “The Molecular Biology of Colorectal Cancer”. Abstract: P004

34. Kashfi K, and Rigas B. (2005) Is COX-2 a “collateral” target in cancer prevention?

Biochemical Society Focused Meeting, Bristol, England. “The Molecular Biology of Colorectal Cancer”. Abstract: P009

35. Kashfi K, Kopelovich L, and Rigas B. (2005) NO-donating aspirin as a novel

chemopreventive agent: Its molecular targets and effects in animal models of cancer. American Association for Cancer Research, 96th Annual Meeting, Anaheim CA. A:2483

36. Kashfi K. (2005) Cancer prevention beyond COX-2. 9th International Conference on

“Eicosanoids & Other Bioactive Lipids in Cancer, Inflammation & Related Diseases”, September 11-14, San Francisco, California.

Page 23 of 27

37. Kashfi K, and Nazarenko A. (2006) Nitric oxide-releasing aspirin suppresses NF-kB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo: An effect through reactive oxygen species. AACR: Fifth Annual International Conference on Frontiers in Cancer Prevention Research, Boston, MA.

38. Nath N, Kogan M, and Kashfi K. (2006) Expression profile of genes altered by NO-donating

aspirin in T-leukemia cells. AACR: Fifth Annual International Conference on Frontiers in Cancer Prevention Research, Boston, MA.

39. Kashfi K, and Borodulina G. (2007) Flurbiprofen benzylnitrate (FBN) inhibits the growth of

various human cancer cells in vitro and prevents intestinal carcinogenesis in Min (APCMin/+) mice. American Association for Cancer Research, 98th Annual Meeting, Los Angeles CA.

40. Kashfi K. (2007) The mechanism of action of nitric oxide-releasing aspirin involves quinone

methides, carbocations, and oxidative stress: Implications for cancer prevention. 10th International Conference on “Eicosanoids & Other Bioactive Lipids in Cancer, Inflammation & Related Diseases”, September 16-19, Montreal, Canada.

41. Kashfi K, Nath, N, and Jacobs L. (2007) Flurbiprofen benzyl nitrate (FBN) modulates ß-

catenin expression and inhibits growth of human epidermoid carcinoma A-431 cells. 10th International Conference on “Eicosanoids & Other Bioactive Lipids in Cancer, Inflammation & Related Diseases”, September 16-19, Montreal, Canada.

42. Nath N, Fallon EA, Patel AM, Saavedra JE, Keefer LK, and Kashfi K. (2008) JS-K, a Nitric

Oxide-Donating Prodrug Inhibits the Growth of Human Colon Cancer Cells: Modulation of ß-catenin/TCF Signaling. American Association for Cancer Research, Annual Meeting, San Diego CA

43. Nath N, Kodela R, Boring D, Crowell JA, and Kashfi K. (2008) Expression profile of genes

altered by ester-protected hydroxybenzyl phosphates (EHBP) in T-leukemia cells. AACR: Seventh Annual International Conference on Frontiers in Cancer Prevention Research, Washington, DC.

44. Nath N, Chattopadhyay M, Pospishil L, Cieciura LZ, Saavedra JE, Keefer LK, and Kashfi K.

(2008) JS-K, a nitric oxide-donating prodrug, inhibits the growth of leukemic Jurkat cells and modulates β-catenin/TCF signaling. AACR: Seventh Annual International Conference on Frontiers in Cancer Prevention Research, Washington, DC.

45. Kodela R, Rokita SE, Boring D, Crowell JA, and Kashfi K. (2008) Bioactivated

chemotherapeutic agents based on ester-protected hydroxybenzyl phosphates (EHBP) for reversible addition to cellular nucleophiles. AACR: Seventh Annual International Conference on Frontiers in Cancer Prevention Research, Washington, DC.

46. Kodela R, Chattopadhyay M, Nath N, Cieciura LZ, Pospishil L, Boring D, Crowell JA, and

Kashfi K. (2008) Ester-protected hydroxybenzyl phosphates (EHBP) inhibit the growth of various cultured human cancer cells: Evidence of a tissue type-independent effect. AACR: Seventh Annual International Conference on Frontiers in Cancer Prevention Research, Washington, DC.

Page 24 of 27

47. Kashfi K. (2009) Ester-protected hydroxybenzyl phosphates (EHBP) as bioactivated selectively reactive chemotherapeutic agents. 11th International Conference on “Bioactive Lipids in Cancer, Inflammation & Related Diseases”. October 25–28 Cancun, Mexico.

48. Chattopadhyay M, Velazquez CV, Keefer LK, and Kashfi K. (2009) Comparison between

NO-ASA and NONO-ASA as safe anti-inflammatory, analgesic, antipyretic, anti-oxidant, chemopreventive prodrugs. AACR: Eighth Annual International Conference on Frontiers in Cancer Prevention Research, December 6-9, Houston, TX.

49. Chattopadhyay M, Goswami S, Nath N, Rodes DB, Saavedra JE, Keefer LK, and Kashfi K.

(2009) JS-K, a nitric oxide-donating prodrug, modulates β-catenin/TCF signaling in leukemic Jurkat cells through S-nitrosylation. AACR: Eighth Annual International Conference on Frontiers in Cancer Prevention Research, December 6-9, Houston, TX.

50. Chattopadhyay M, Goswami S, Kodela R, Boring D, Crowell JA, and Kashfi K. (2010) Nitric

oxide-releasing NSAIDs suppress NF-κB signaling and increase caspase-3 enzyme activity in vitro and in vivo through S-nitrosylation. American Association for Cancer Research, 101st Annual Meeting, April 17-21, Washington DC.

51. Kashfi K, Mynatt RL, Park EA, Cook GA. (2011) Phospholipid activation of mitochondrial

membrane CPT-I and recombinant CPT-II. Recent advances in membrane biochemistry, Biochemical Society meeting, January 5-7, Robinson College, Cambridge, UK.

52. Langone P, Curcio GM, Kodela R, Kashfi K, Dolai S, Raja K, Banerjee P. (2011) Drug

targeting to eliminate breast and brain tumors. American Association for Cancer Research, Chemistry in Cancer Research: The Biological Chemistry of Inflammation As a Cause of Cancer conference. January 30th-February 2nd San Diego, CA.

53. Chattopadhyay M, Kodela R, Banerjee P, Boring D, Crowell JA, and Kashfi K. (2011)

Hydrogen sulfide-releasing NSAIDs for prevention and treatment of colon and breast cancers. American Association for Cancer Research, Chemistry in Cancer Research: The Biological Chemistry of Inflammation As a Cause of Cancer conference. January 30th-February 2nd San Diego, CA.

54. Gan ZY, Kodela R, Goswami S, Chattopadhyay M, Boring D, Crowel JA, and Kashfi K.

(2011) All three positional isomers of acetyl salicylic acids are equally potent in inhibiting colon cancer cell growth: Differences in mode of COX inhibition. American Association for Cancer Research, 102nd Annual Meeting, April 2-6, Orlando FL.

55. Barsegian A, Chattopadhyay M, Kodela R, Boring D, Crowel JA, and Kashfi K. (2011)

Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. American Association for Cancer Research, 102nd Annual Meeting, April 2-6, Orlando FL.

56. Dastagirzada YM, Street CR, Nesbitt DE, Gan ZY, Barsegian A, Chattopadhyay M, Kodela R,

Boring D, Crowel JA, and Kashfi K. (2011) Hydrogen sulfide-releasing NSAIDs inhibit the growth of cultured human cancer cells: A general property and evidence of a tissue type-independent effect. American Association for Cancer Research, 102nd Annual Meeting, April 2-6, Orlando FL.

57. Gan ZY, Chattopadhyay M, Kodela R, Boring D, Crowel JA, and Kashfi K. (2011) Hydrogen

sulfide-releasing aspirin inhibits the growth of leukemic Jurkat cells and modulates β-

Page 25 of 27

catenin expression. American Association for Cancer Research, 102nd Annual Meeting, April 2-6, Orlando FL.

58. Street CR, Chattopadhyay M, Kodela R, Boring D, Crowel JA, and Kashfi K. (2011)

Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo. American Association for Cancer Research, 102nd Annual Meeting, April 2-6, Orlando FL.

59. Nesbitt DE, Chattopadhyay M, Kodela R, Boring D, Crowel JA, and Kashfi K. (2011)

Hydrogen sulfide-releasing naproxen inhibits HT-29 human colon cancer cell growth: Modulation of NF-κB. American Association for Cancer Research, 102nd Annual Meeting, April 2-6, Orlando FL.

60. Kashfi K. (2011) Therapeutic potential of hydrogen sulfide-releasing NSAIDs. 12th

International Conference on “Bioactive Lipids in Cancer, Inflammation & Related Diseases”. September 8-12 Seattle, Washington.

61. Kashfi K. (2011) Therapeutic potential of hydrogen sulfide-releasing NSAIDs. “Zing” Cancer

Conference. November 9-13, Xcaret, Mexico. 62. Aldawsari F, Chattopadhyay M, Yoo J, Rao PPN, Medina-Franco J, Kashfi K, Velázquez C.

(2012) Design, synthesis and biological evaluation of resveratrol analogues as anti-inflammatory and potential chemopreventive agents. American Chemical Society National Meeting & Exposition, March 25-29, San Diego CA.

63. Vannini F, Han-Bee Kim HB, Chattopadhyay M, Kodela R, and Kashfi K. (2012) NOSH

compounds: Nitric oxide- and hydrogen sulfide-releasing hybrids, a new class of anti-inflammatory pharmaceuticals. American Association for Cancer Research, 103rd Annual Meeting, March 31-Aprin 4, Chicago IL.

64. Street CA, Chattopadhyay M, Kodela R, and Kashfi K. (2012) NOSH-aspirin, a novel nitric

oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth. American Association for Cancer Research, 103rd Annual Meeting, March 31-Aprin 4, Chicago IL.

65. Lee DH, Nesbitt DE, Chattopadhyay M, Kodela R, and Kashfi K. (2012) NOSH-aspirin a

novel nitric oxide- and hydrogen sulfide-releasing hybrid for treatment of colon cancer. American Association for Cancer Research, 103rd Annual Meeting, March 31-Aprin 4, Chicago IL.

66. Chattopadhyay M, Kodela R, Rodriguez-Dimitrescu A, Velazquez-Martinez CA, and Kashfi K. (2012) Pharmacological modulation of forkhead box M1 (FoxM1) transcription factor in cancer chemoprevention and treatment. Western Canadian Medicinal Chemistry Workshop (WCMCW) September 28-30, Saskatoon, SK, Canada. 67. Chattopadhyay M, Kodela R, Lee DH, Le T-TC, and Kashfi K. (2012) NOSH-aspirin (NBS-

1120) a dual nitric oxide and hydrogen sulfide releasing hybrid for treatment of cancer. AACR: Eleventh Annual International Conference on Frontiers in Cancer Prevention Research, October 16-19, Anaheim, CA.

68. Chattopahyay M, Kodela R, Rodriguez-Dimitrescu A, Velazquez-Martinez CA, Kashfi K.

(2012) Pharmacological modulation of the forkhead box M1 (FOXM1) transcription factor

Page 26 of 27

in cancer chemoprevention and treatment. Poster: Cancer Research Conference (Alberta Cancer Foundation), November 1-3, Banff, Alberta. Canada.

69. Chattopadhyay M, Kodela R, Rodriguez-Dimitrescu A, Velázquez-Martínez CA, Kashfi K.

(2012) Pharmacological modulation of forkhead box M1 (FoxM1) transcription factor in cancer chemoprevention and treatment. Oral presentation at the 3rd Western Canadian Medicinal Chemistry Workshop. Saskatoon, SK. September 29th 2012

70.Aldawsari F, Chattopadhyay M, Yoo J, Rao PNP, Medina-Franco J, Kashfi K, Velazquez- Martinez CA. (2012) Design, synthesis, and biological evaluation of resveratrol analogues as anti-inflammatory and potential chemopreventive agents. Cancer Research Conference (Alberta Cancer Foundation), November 1-3, Banff, Alberta. Canada. 71. Eschbach EK, MacKessack-Leitch AC, Vannini F, Kodela R, Chattopadhyay M, Kashfi K. (2013) NOSH-aspirin is a potent inhibitor of colon cancer cell growth: Effects of positional isomerism. American Association for Cancer Research, Annual Meeting, April 6-10, Washington DC. 72. Nesbitt DE, Chattopadhyay M, Vannin V, Le TC, Kodela R, Nath N, Kashfi K. (2013) NOSH- aspirin inhibits breast cancer cell growth: An effect modulated through reactive oxygen species and independent of the ER status. American Association for Cancer Research, Annual Meeting, April 6-10, Washington DC. 73. Nia KV, Kodela R, Chattopadhyay M, and Kashfi K. (2013) The dual nitric oxide and hydrogen sulfide-releasing nonsteroidal anti-inflammatory drugs, NOSH-aspirin, NOSH- naproxen, and NOSH-sulindac are safe to the stomach and have strong anti- inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties. Digestive Disease Week, May 18-21 Orlando, FL. 74. Aldawsari F, Chattopadhya, M, Yoo J, Rao PNP, Medina-Franco J, Kashfi K, Velazquez-

Martinez CA. (2013) Design, synthesis, and biological evaluation of resveratrol analogues as anti-inflammatory and potential chemopreventive agents. Oral presentation at the 96th Canadian Chemistry Conference & Exhibition. Quebec, QC. May 30th.

75. Rodriguez-Dimitrescu A, Chattopahyay M, Kodela R, Kashfi K, Velázquez-Martínez CA.

(2013) Pharmacological modulation of forkhead box M1 (FoxM1) transcription factor in cancer chemoprevention and treatment Oral presentation at the 96th Canadian Chemistry Conference & Exhibition. Quebec, QC. May 30th.

76. Kashfi K, Chattopadhyay M, Kodela R, Song T. (2013) NOSH-aspirin a dual nitric oxide-and

hydrogen sulfide-releasing hybrid reciprocally regulates NF-κB: S-nitrosylation vs S-sulfhydration. The FASEB Journal. 2013;27:890.23

77. Martinez CJ, Chattopadhyay M, and Kashfi K. (2014) NOSH-aspirin and 5-fluorouracil

demonstrate synergistic efficacy in a xenograft model of colon cancer. American Association for Cancer Research, Annual Meeting, April 6-9, San Diego CA.

78. Soyemi SA, Chattopadhyay M, and Kashfi K. (2014) NOSH-aspirin alone or in combination

with 5-fluorouracil induces tumor regression in a xenograft model of estrogen receptor positive breast cancer. American Association for Cancer Research, Annual Meeting, April 6-9, San Diego CA.

Page 27 of 27

79. Nia KV, Chattopadhyay M, Metkar S, Kodela R, Kvint S, and Kashfi K. (2014) Targeting NF-κB, FoxM1, and p53 in pancreatic cancer with NOSH-aspirin. Digestive Disease Week, May 4-6 Chicago, IL.

80. Antoniou C, Chatzimichail G, Kashfi K, Fotopoulos F. (2014) Exploring the potential of

NOSH-aspirin as a plant priming agent against abiotic stress factors. Third International Conference on Hydrogen Sulfide in Biology and Medicine. June 4-6, Kyoto Japan.

81. Duvalsaint PL, Chattopadhyay M, Kodela R, Kashfi K. (2016) NOSH-Aspirin (NBS-1120)

Inhibits Estrogen Receptor Negative Breast Cancer in Vitro and in Vivo by Modulating Redox-Sensitive Signaling Pathways. Experimental Biology, April 2-6, San Diego CA.

The FASEB Journal. 82. Duvalsaint PL, Chattopadhyay M, Kodela R, Kashfi K. (2016) Molecular targets of NOSH-

naproxen a dual nitric oxide and hydrogen sulfide-releasing hybrid in a xenograft mouse model of colon cancer. American Association for Cancer Research Annual Meeting, April 16-20, New Orleans, Louisiana.

83. Kashfi K. (2016) Molecular targets of NOSH-aspirin in colon cancer: modulation of FoxM1,

ß-catenin, NF-kB, and caspase-3 through S-notrosylation, S-sulfhydration and reactive oxygen species. Biochemical Society Irish Area Section, “Inflammatory diseases - mechanisms and clinical perspectives”. November 3-4, Maynooth University, Ireland.

84. Ghasemi A, Kashfi K, Jeddi S, Gheibi S. (2018) Dose-dependent effects of hydrogen sulfide

on glucose tolerance in obese type 2 diabetic rats. Seoul International Congress of Endocrinology and Metabolism. April 19- 22; Seoul, Korea.

85. Scicinski J, El-Miniawi M, Zahran T, and Kashfi K. (2019) The novel nitric oxide and

hydrogen sulfide releasing anti-cancer agent, NBS-1120, protects the GI tract from the ulcerogenic activity of aspirin and naproxen. American Association for Cancer Research Annual Meeting, March 29 - Apr 3, Atlanta, Georgia.

86. Kashfi K, Gheibi S, Jeddi S, Ghasemi A. (2019) Effects of hydrogen sulfide on carbohydrate

metabolism and blood pressure in obese type-2 diabetic rats. Experimental Biology, April 6-9, Orlando, Florida. The FASEB Journal.

87. Santiago G, Chattopadhyay M, Kodela R, Nath N, and Kashfi K. (2019) Reactive oxygen

species modulates the molecular targets of NBS-1120 in pancreatic cancer. Experimental Biology, April 6-9, Orlando, Florida. The FASEB Journal.

88. Ghasemi A, Gheibi S, Jeddi S, Carlström M, Kashfi K. (2019) Co-administration effects of

nitrite and sodium hydrosulfide on oxidative stress in type 2 diabetic rats. The 7th Seoul International Congress of Endocrinology and Metabolism. April 18- 24; Seoul, Korea.

89. Gheibi S, Jeddi S, Carlström M, Kashfi K, Ghasemi A. (2019) Sodium hydrosulfide increases the protective effects of nitrite on carbohydrate metabolism in type 2 diabetic rats. The 7th Seoul International Congress of Endocrinology and Metabolism. April 18- 24; Seoul, Korea.